Cargando…

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme

Introduction Patients with glioblastoma multiforme (GBM) over age 65 represent nearly half of those diagnosed per annum. They have a different tumor markers profile, physiologic reserve, and a median survival as low as three to four months. An optimal treatment strategy in older GBM patients remains...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greer, Liana, Pannullo, Susan C., Smith, Andrew W, Taube, Shoshana, Yondorf, Menachem Z, Parashar, Bhupesh, Trichter, Samuel, Nedialkova, Lucy, Sabbas, Albert, Christos, Paul, Wernicke, A. Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524564/ https://www.ncbi.nlm.nih.gov/pubmed/28775928 http://dx.doi.org/10.7759/cureus.1388

Ejemplares similares

Placement of (131)Cs permanent brachytherapy seeds in a large combined cavity of two resected brain metastases in one setting: case report and technical note
por: Greenwald, Jacelyn, et al.
Publicado: (2019)

Innovative Hypofractionated Stereotactic Regimen Achieves Excellent Local Control with No Radiation Necrosis: Promising Results in the Management of Patients with Small Recurrent Inoperable GBM
por: Jia, Angela, et al.
Publicado: (2016)

Dosimetric differences between cesium-131 and iodine-125 brachytherapy for the treatment of resected brain metastases
por: Yondorf, Menachem Z., et al.
Publicado: (2020)

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme
por: Jastaniyah, Noha, et al.
Publicado: (2013)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide
por: Gebhardt, Brian J, et al.
Publicado: (2014)

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
por: Shields, Lisa BE, et al.
Publicado: (2013)

Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide
por: Gregucci, Fabiana, et al.
Publicado: (2021)

Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study
por: Greenspoon, Jeffrey Noah, et al.
Publicado: (2014)

Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide
por: Topkan, Erkan, et al.
Publicado: (2020)

Excellent Outcomes in a Geriatric Patient with Multiple Brain Metastases Undergoing Surgical Resection with Cesium-131 Implantation and Stereotactic Radiosurgery
por: Mahase, Sean S, et al.
Publicado: (2017)

Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice
por: van Genugten, J. A. B., et al.
Publicado: (2009)

Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems
por: Toren, Amos, et al.
Publicado: (2016)

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide
por: Wang, Nan, et al.
Publicado: (2021)

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience
por: Zhong, Liangzhi, et al.
Publicado: (2019)

Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide
por: Faustino, Alexandre Ciuffi, et al.
Publicado: (2020)

Clinical comparison of brachytherapy versus hypofractionated external beam radiation versus standard fractionation external beam radiation for non-melanomatous skin cancers
por: Haseltine, Justin M, et al.
Publicado: (2016)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Hypofractionated High-Dose Irradiation with Positron Emission Tomography Data for the Treatment of Glioblastoma Multiforme
por: Miwa, Kazuhiro, et al.
Publicado: (2014)

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
por: Rosenfeld, Myrna R, et al.
Publicado: (2014)

Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide
por: Topkan, Erkan, et al.
Publicado: (2020)

Preparation of Temozolomide-Loaded Nanoparticles for Glioblastoma Multiforme Targeting—Ideal Versus Reality
por: Lee, Chooi Yeng, et al.
Publicado: (2016)

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models
por: Valtorta, Silvia, et al.
Publicado: (2017)

Hypofractionated short‐course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the National Cancer Database
por: Mak, Kimberley S., et al.
Publicado: (2017)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma
por: Kim, Nalee, et al.
Publicado: (2023)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
por: Nguyen, Ludovic T., et al.
Publicado: (2013)

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
por: Heynckes, Sabrina, et al.
Publicado: (2019)

HGG-04. ZINC ENHANCES TEMOZOLOMIDE CYTOTOXICITY IN PEDIATRIC GLIOBLASTOMA MULTIFORME MODEL SYSTEM
por: Toren, Amos, et al.
Publicado: (2020)

Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes
por: Pham, Anthony, et al.
Publicado: (2015)

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
por: Yung, W K A, et al.
Publicado: (2000)

Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme
por: Aherne, Noel J., et al.
Publicado: (2014)

Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment
por: Jakubowicz-Gil, Joanna, et al.
Publicado: (2013)

Elimination of Cancer Stem-Like Cells and Potentiation of Temozolomide Sensitivity by Honokiol in Glioblastoma Multiforme Cells
por: Lai, I-Chun, et al.
Publicado: (2015)

In Vitro Radiosensitizing Effects of Temozolomide on U87MG Cell Lines of Human Glioblastoma Multiforme
por: Borhani, Samira, et al.
Publicado: (2017)

Temozolomide in Combination With NF-κB Inhibitor Significantly Disrupts the Glioblastoma Multiforme Spheroid Formation
Publicado: (2020)

Glutathione S-Transferase M3 Is Associated with Glycolysis in Intrinsic Temozolomide-Resistant Glioblastoma Multiforme Cells
por: Cheng, Shu-Yu, et al.
Publicado: (2021)

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
por: Nishri, Yossi, et al.
Publicado: (2022)

Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide
por: Feng, Shao-Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nejckba3dnp4rfg91hidj8oeil